AJOVY

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0052	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	27/03/2025		SmPC, Annex II and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IB/0051	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	23/10/2024	n/a		
IA/0050	A.7 - Administrative change - Deletion of manufacturing sites	17/09/2024		Annex II and PL	
IB/0048	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	19/06/2024	n/a		
IB/0049	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	17/06/2024	n/a		
II/0047	Submission of the final report from the PASS study TV48125-MH-50039 listed as a category 3 study in the RMP. This is a long-term, prospective, observational study to evaluate the safety, including cardiovascular safety, of fremanezumab in patients with migraine in routine clinical practice. The RMP version 6.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	11/04/2024	n/a		Submission of the final report from the PASS study TV48125-MH-50039.
PSUSA/10758 /202309	Periodic Safety Update EU Single assessment - fremanezumab	11/04/2024	n/a		PRAC Recommendation - maintenance

IB/0046	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	21/12/2023	n/a		
R/0044	Renewal of the marketing authorisation.	14/09/2023	06/11/2023		Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of AJOVY in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0041/G	This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of	11/08/2023	n/a		

	specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits				

IB/0043	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	06/07/2023	n/a		
IB/0042	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	26/06/2023	n/a		
II/0039	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	12/05/2023	n/a		
IB/0040	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	08/05/2023	n/a		
PSUSA/10758 /202209	Periodic Safety Update EU Single assessment - fremanezumab	14/04/2023	n/a		PRAC Recommendation - maintenance
IB/0038	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	28/02/2023	n/a		
IB/0035/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters	25/01/2023	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
IA/0037/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	06/12/2022	n/a		
IA/0034	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	22/08/2022	n/a		
IB/0033	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	12/08/2022	n/a		
N/0032	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	02/06/2022	27/04/2023	PL	

IB/0031	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	06/05/2022	27/04/2023	SmPC and PL	
II/0029	Submission of an updated RMP version 3.0 in line with the PI changes which were implemented following the assessment of PSUSA/202103 with regards to severe hypersensitivity reactions. The MAH has also taken the opportunity to update the PASS details according to the latest approved PASS protocols. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	07/04/2022	n/a		Submission of an updated RMP version 3.0 to remove severe hypersensitivity reactions from the list of important potential risks and update PASS protocols.
PSUSA/10758 /202109	Periodic Safety Update EU Single assessment - fremanezumab	07/04/2022	n/a		PRAC Recommendation - maintenance
IB/0030	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	24/03/2022	n/a		
IB/0028/G	This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	27/01/2022	n/a		

	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place				
PSUSA/10758 /202103	Periodic Safety Update EU Single assessment - fremanezumab	14/10/2021	13/12/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10758/202103.
IA/0027/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.f.1.e - Stability of FP - Change to an approved stability protocol	07/12/2021	n/a		
IB/0025	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	03/11/2021	n/a		
II/0022	B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method	09/09/2021	n/a		
IB/0024	B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits	20/08/2021	n/a		

IB/0023	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	05/08/2021	n/a		
IB/0021	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation	25/06/2021	n/a		
IB/0018/G	This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	23/06/2021	22/09/2021	SmPC, Labelling and PL	To change the storage conditions and extend the shelf-life.
IA/0019	B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	20/05/2021	n/a		
PSUSA/10758 /202009	Periodic Safety Update EU Single assessment - fremanezumab	09/04/2021	n/a		PRAC Recommendation - maintenance
IA/0017	B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	05/03/2021	n/a		

IB/0016	B.II.b.z - Change in manufacture of the Finished Product - Other variation	05/03/2021	n/a		
IB/0014/G	This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure	09/02/2021	n/a		
PSUSA/10758 /202003	Periodic Safety Update EU Single assessment - fremanezumab	01/10/2020	n/a		PRAC Recommendation - maintenance
IB/0013	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation	24/09/2020	n/a		
II/0011	B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	03/09/2020	n/a		
II/0008/G	This was an application for a group of variations.	03/09/2020	22/09/2021	SmPC, Labelling and	

	A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data			PL	
IB/0010	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	07/08/2020	n/a		
IA/0012/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.f.1.e - Stability of FP - Change to an approved stability protocol	29/07/2020	n/a		
PSUSA/10758 /201909	Periodic Safety Update EU Single assessment - fremanezumab	30/04/2020	26/06/2020	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10758/201909.
IA/0007	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test	17/03/2020	n/a		

	procedure				
IB/0005	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	08/01/2020	n/a		
II/0003	Update of section 4.8 of the SmPC in order to update the safety information based on final results from study TV48125-CNS-30051 listed as a category 3 study in the RMP; A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	28/11/2019	26/06/2020	SmPC and Labelling	Section 4.8 of the SmPC has been updated to reflect immunogenicity information from study TV48125-CNS-30051; A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine.
IAIN/0004	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	26/11/2019	26/06/2020	SmPC, Labelling and PL	
II/0002	B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products	24/10/2019	26/06/2020	SmPC, Labelling and PL	

IAIN/0001/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	10/05/2019	n/a		